UMB Bank n.a. Has $106,000 Holdings in IQVIA Holdings Inc. $IQV

UMB Bank n.a. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 150.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 675 shares of the medical research company’s stock after buying an additional 406 shares during the period. UMB Bank n.a.’s holdings in IQVIA were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in IQV. Brighton Jones LLC increased its stake in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Vise Technologies Inc. acquired a new position in IQVIA during the fourth quarter worth approximately $254,000. Toronto Dominion Bank raised its stake in IQVIA by 2.2% in the fourth quarter. Toronto Dominion Bank now owns 61,774 shares of the medical research company’s stock valued at $12,139,000 after buying an additional 1,358 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $25,152,000. Finally, Mattson Financial Services LLC boosted its stake in shares of IQVIA by 20.9% during the 4th quarter. Mattson Financial Services LLC now owns 5,844 shares of the medical research company’s stock worth $1,148,000 after acquiring an additional 1,011 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on IQV shares. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Barclays raised their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 23rd. Mizuho upped their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Evercore ISI upped their target price on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, July 9th. Eighteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $229.64.

IQVIA Trading Down 2.8%

Shares of IQV stock opened at $181.25 on Thursday. The stock has a market cap of $30.81 billion, a P/E ratio of 26.23, a price-to-earnings-growth ratio of 2.05 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $238.56. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock has a 50 day simple moving average of $186.37 and a 200 day simple moving average of $167.39.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the previous year, the firm earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.